Boryung Pharm challenges KRW 240 billion sales with the antihypertensive ‘Kanarb’

Boryung Pharm will challenge KRW 240 sales with ‘Kanarb(antihypertensive),’ the 15^th domestic new drug, by 2020.

According to Boryung Pharm, the company is planning to expand its domestic and foreign markets with various complexes, such as CCB and hyperlipidemia complexes, starting with ‘Kanarb Tab(generic name: fimasartan).’

As a part of the plan, it is planning to launch a CCB complex(fimas...